Jaap Goudsmit

This inventor holds 20 USPTO granted patents and 10 published patent applications, plus 6 CIPO patents and 9 EPO patents. Top assignees: Janssen Vaccines & Prevention B.v., Ac Immune Sa, Biomerieux, Inc.. Active years: 1996-2024.

USPTO Granted Patents = 20 (Patent Applications = 10)

% Patents Active = 65.0

CIPO Patents = 6 (Patent Applications = 11)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 4.5

ph-index = 8

Forward Citations = 217(Granted Patents)

Location History:

Leiden, NL (2019 - 2020)
Amsterdam, NL (1996 - 2024)

Company Filing History:

5 out of 117

Janssen Vaccines & Prevention B.v.

Janssen Pharmaceuticals, Inc.

patents

6. 3 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

7. 2 out of 1,217

The United States of America as Represented by the Department of Health

International Aids Vaccine Initiative

patents

where one patent can have more than one assignee

Years Active: 1996-2024

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11958889 - Compositions of phosphorylated tau peptides and uses thereof (2024-04-16),

2. 11591377 - Heterologous administration of tau vaccines (2023-02-28),

3. 11472869 - Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau (2022-10-18),

4. 11124552 - Compositions of phosphorylated tau peptides and uses thereof (2021-09-21),

5. 10562963 - Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau (2020-02-18),

6. 10400034 - Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau (2019-09-03),

7. 10301379 - Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau (2019-05-28),

8. 9701718 - Adenovirus serotype 26 and serotype 35 filovirus vaccines (2017-07-11),

9. 9074262 - Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of HIV-1 (2015-07-07),

10. 9012618 - Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures (2015-04-21),

11. 8697352 - Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of HIV-1 (2014-04-15),

12. 8106170 - Compositions against SARS-coronavirus and uses thereof (2012-01-31),

13. 8101739 - Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector (2012-01-24),

14. 7696330 - Binding molecules against SARS-coronavirus and uses thereof (2010-04-13),

15. 7425437 - Vaccines against West Nile Virus (2008-09-16),

Title: Jaap Goudsmit - Pioneering Inventor from Amsterdam

Introduction: Jaap Goudsmit is a distinguished inventor hailing from Amsterdam, Netherlands, known for his groundbreaking contributions to the field of biotechnology and medical research.

Latest Patents: Jaap Goudsmit holds several patents in the areas of vaccine development, infectious diseases, and immunology, showcasing his innovative approach to solving complex health challenges.

Career Highlights: With a career spanning over three decades, Goudsmit has held prominent positions in leading research institutions and biotech companies, where he has spearheaded numerous projects that have revolutionized the medical landscape.

Collaborations: Throughout his career, Jaap Goudsmit has collaborated with top scientists, researchers, and pharmaceutical companies worldwide, fostering a culture of innovation and knowledge exchange in the scientific community.

Conclusion: Jaap Goudsmit's relentless pursuit of scientific excellence and his passion for innovation have solidified his reputation as a visionary inventor in the field of biotechnology, leaving an indelible mark on the world of medical research.